Skip to cookie consent Skip to main content

Advancing Innovation in Healthcare

Harnessing the power of scientific innovation to create truly novel products for the market benefit of patients worldwide.

Learn more about us
person holding transparant screen with brain image and statistics

Investing in early-stage venture capital

We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. 

Leveraging a competitive advantage

Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. 

#1 in hospital medical research​

Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ 

Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce.

Learn more about our investment strategy
Brigham and Women's Hospital at night

Legacy of investing in medical innovation

Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham.

  • illustration of crispr technololgy
    Editas Medicine

    IPO Feb. 2016 (NASDAQ: EDIT) 

    Unlocking the power and potential of CRISPR genome editing technology.

  • illustration of virus
    CoStim Pharmaceuticals

    Acquired by Novartis, Feb. 2014

    Next-generation immuno-oncology drugs based on T-cell costimulatory targets.

     

  • magnified view of blood cells
    Keros Therapeutics

    IPO April 2020 (NASDAQ: KROS)

    Novel treatments for patients suffering from hematologic and musculoskeletal disorders.

"Mass General Brigham Ventures is helping advance the Mass General Brigham mission by investing in bold, transformative ideas that leverage our strength and depth in world-class science and research."

Anne Klibanski, MD
President & CEO, Mass General Brigham